Chung-Ming Chu

Chung-Ming Chu

Auto-generated profile, based on publicly available information

Chung-Ming Chu

Department of Medicine, United Christian Hospital

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Thorax
Verified
Journal Article
Open access
PDF file
CCC M Chu
C M Chu
VCV C C Cheng
V C C Cheng
Ivan FN HungIvan FN Hung
Ivan FN Hung
MWM M L Wong
M M L Wong
KCK H Chan
K H Chan
HGHKU/UCH SARS Study Group
HKU/UCH SARS Study Group
Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents. Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients treated with ribavirin only who served as historical controls. Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and ribavirin at concentrations of 4 µg/ml and 50 µg/ml, respectively, only at 48 hours. The adverse clinical outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls (2.4% v 28.8%, p<0.001) at day 21 after the onset of symptoms. The adverse outcome remained significantly lower in the treatment group than in the controls—both those diagnosed early (p<0.001) and those diagnosed later in the course of the epidemic (p = 0.002)—but there was no significant difference in adverse outcome rates between the two time periods (p = 0.548). No time related difference in outcome was observed in the control groups. A reduction in steroid usage and nosocomial infections was seen in patients initially treated with lopinavir/ritonavir, and these patients had a decreasing viral load and rising peripheral lymphocyte count. Multivariate analysis showed that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome. Lopinavir/ritonavir treatment was associated with a better outcome even when adjusted for baseline lactate dehydrogenase level. Conclusions: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS.

15 January 2005 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
Patrick WooPatrick Woo
Patrick Woo
SLSusanna K. P. Lau
Susanna K. P. Lau
CCChung-Ming Chu
Chung-Ming Chu
KCKwok-Hung Chan
Kwok-Hung Chan
HTHoi-Wah Tsoi
Hoi-Wah Tsoi
KYKwok-Yung Yuen
Kwok-Yung Yuen
Despite extensive laboratory investigations in patients with respiratory tract infections, no microbiological cause can be identified in a significant proportion of patients. In the past 3 years, several novel respiratory viruses, including human metapneumovirus, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and human coronavirus NL63, were discovered. Here we report the discovery of another novel coronavirus, coronavirus HKU1 (CoV-HKU1), from a 71-year-old man with pneumonia who had just returned from Shenzhen, China. Quantitative reverse transcription-PCR showed that the amount of CoV-HKU1 RNA was 8.5 to 9.6 × 10 6 copies per ml in his nasopharyngeal aspirates (NPAs) during the first week of the illness and dropped progressively to undetectable levels in subsequent weeks. He developed increasing serum levels of specific antibodies against the recombinant nucleocapsid protein of CoV-HKU1, with immunoglobulin M (IgM) titers of 1:20, 1:40, and 1:80 and IgG titers of <1:1,000, 1:2,000, and 1:8,000 in the first, second and fourth weeks of the illness, respectively. Isolation of the virus by using various cell lines, mixed neuron-glia culture, and intracerebral inoculation of suckling mice was unsuccessful. The complete genome sequence of CoV-HKU1 is a 29,926-nucleotide, polyadenylated RNA, with G+C content of 32%, the lowest among all known coronaviruses with available genome sequence. Phylogenetic analysis reveals that CoV-HKU1 is a new group 2 coronavirus. Screening of 400 NPAs, negative for SARS-CoV, from patients with respiratory illness during the SARS period identified the presence of CoV-HKU1 RNA in an additional specimen, with a viral load of 1.13 × 10 6 copies per ml, from a 35-year-old woman with pneumonia. Our data support the existence of a novel group 2 coronavirus associated with pneumonia in humans.

1 May 2003 in The Lancet
Verified
Journal Article
Closed access
JNJohn M Nicholls
John M Nicholls
LPLeo Poon
Leo Poon
KLKam C Lee
Kam C Lee
WNWai F Ng
Wai F Ng
SLSik T Lai
Sik T Lai
JPJs Malik Peiris
Js Malik Peiris

1 July 2009 in General Hospital Psychiatry
Verified
Journal Article
Closed access
IMIvan Wing Chit Mak
Ivan Wing Chit Mak
CCChung Ming Chu
Chung Ming Chu
PPPey Chyou Pan
Pey Chyou Pan
MYMichael Gar Chung Yiu
Michael Gar Chung Yiu
VCVeronica Lee Chan
Veronica Lee Chan

1 June 2004 in The Canadian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
SCSiew E Chua
Siew E Chua
VCVinci Cheung
Vinci Cheung
CCCharlton Cheung
Charlton Cheung
GMGrainne M McAlonan
Grainne M McAlonan
JWJosephine Ws Wong
Josephine Ws Wong
KTKenneth Wt Tsang
Kenneth Wt Tsang
Objective: To quantify stress and the psychological impact of severe acute respiratory syndrome (SARS) on high-risk health care workers (HCWs). Method: We evaluated 271 HCWs from SARS units and 342 healthy control subjects, using the Perceived Stress Scale (PSS) to assess stress levels and a structured list of putative psychological effects of SARS to assess its psychological effects. Healthy control subjects were balanced for age, sex, education, parenthood, living circumstances, and lack of health care experience. Results: Stress levels were raised in both groups (PSS = 18) but were not relatively increased in the HCWs. HCWs reported significantly more positive (94%, n = 256) and more negative psychological effects (89%, n = 241) from SARS than did control subjects. HCWs declared confidence in infection-control measures. Conclusions: In HCWs, adaptive responses to stress and the positive effects of infection control training may be protective in future outbreaks. Elevated stress in the population may be an important indicator of future psychiatric morbidity.

1 February 2004 in Emerging Infectious Diseases
Verified
Journal Article
Open access
KLKwok-Kwong Lau
Kwok-Kwong Lau
WYWai-Cho Yu
Wai-Cho Yu
CCChung-Ming Chu
Chung-Ming Chu
SLSuet-Ting Lau
Suet-Ting Lau
BSBun Sheng
Bun Sheng
KYKwok-Yung Yuen
Kwok-Yung Yuen
On day 22 of illness, generalized tonic-clonic convulsion developed in a 32-year-old woman with severe acute respiratory syndrome (SARS). Cerebrospinal fluid tested positive for SARS coronavirus (SARS-CoV) by reverse transcriptase–polymerase chain reaction. SARS-CoV may have caused an infection in the central nervous system in this patient.